)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
AcuCort
AcuCort (ACUC) investor relations material
AcuCort Status update summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Status update summary9 Nov, 2026
Canadian agreement
Exclusive licence and distribution agreement gives Kye rights to register, market, distribute and sell Zeqmelit in Canada.
Regulatory submission planned for early 2027; launch expected in 2028, subject to Health Canada marketing authorisation.
Terms include an upfront payment, regulatory and other milestone payments, product-supply revenue, and royalties on net sales.
Partner and strategy
Kye launched seven innovative prescription products in Canada since 2024 and has an established presence in relevant segments, including paediatrics.
Kye plans to use its paediatric sales organisation and extend Zeqmelit’s reach into allergy and respiratory diseases.
Agreement advances international commercialization through established partners; Canada has more than 40 million people.
Commercial footprint
Zeqmelit is marketed in Sweden, Denmark, Norway and Finland.
Existing Glenmark agreement covers Germany, the Netherlands, the Czech Republic, Austria, Slovakia and Ukraine.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from AcuCort
- Q3 losses widened as Zeqmelit® expansion and a ~SEK 70.3m rights issue advanced.ACUC
Q3 2026 - Sales surged in the Nordics, with regulatory progress and partnerships paving the way for global expansion.ACUCQ2 2026
- ZeqmelitⓇ offers fast, user-friendly allergy relief, expanding across Europe with strong clinical and market support.ACUCLife Science Conference 2026
- Net loss of -6,833 KSEK in Q1 2026; major EU deal and FDA progress for US entry.ACUCQ1 2026
- Strategic partnerships and capital raise position Zeqmelit® for international expansion despite ongoing losses.ACUCQ4 2025
- Losses increased as ZeqmelitⓇ launched in Denmark and global expansion accelerated.ACUCQ3 2025
- First sales achieved, international expansion underway, and cash position strengthened.ACUCQ2 2025
- First Zeqmelit® sales recorded; expansion and regulatory progress drive future growth.ACUCQ3 2024
- ZeqmelitⓇ launch delay led to no H1 revenue, but clinical and regulatory progress remains strong.ACUCQ2 2024
Next AcuCort earnings date
Q4 202619 Feb, 2027
AcuCort
Next AcuCort earnings date
Q4 202619 Feb, 2027
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
AcuCort is a biotechnology company that develops smart medicines for the treatment of chronic diseases, with a focus on pain. Their mission is to identify, develop and commercialize innovative products that meet the patient’s need for convenient and effective treatment.